Dr. Bordbar is the co-founder and Chief Technology Officer of Sinopia Biosciences, a clinical stage biotechnology company advancing novel therapeutics from its computational drug discovery platform. He has over a decade of experience in systems biology and bioinformatics, applying mechanistic and statistical models to large datasets. His computational predictions have led to numerous scientific discoveries and successful pre-clinical and IRB-approved research studies. Dr. Bordbar has served as the principal investigator on 12 grants from the National Institutes of Health and The Michael J. Fox Foundation since 2014. He has published 30+ peer-reviewed publications with over 5,000 citations, including several in the top one percent of cited papers in their respective fields, and is an inventor on all of Sinopia’s intellectual property. He received his PhD from the University of California, San Diego, was awarded the Charles Lee Powell Foundation fellowship and is a Gordon Scholar in engineering leadership.
Associated Grants
-
First-in-human Phase 1a Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending doses of SB-0110 after Oral Administration in Healthy Subjects
2024
-
Evaluating the Safety, Tolerability and Potential Efficacy of SB-0107 for Treating Parkinson’s Disease and Levodopa-Induced Dyskinesia
2021
-